Upcoming Research Opportunities

Open opportunities (fellowships, awards, training, research, funding, career, etc.) of interest to NEALS members can be found here. Please contact Christina Smith, NEALS Communications Coordinator, at csmith@neals.org to submit an announcement for posting on the website.

Neals logo

The scholarship application is open May 12 through June 16, 2025 at 2 PM Eastern. https://everylifefoundation.org/segalman/ [everylifefoundation.org]

After six successful years of the #RAREis Scholarship Fund [everylifefoundation.org], the EveryLife Foundation is proud to launch a new initiative: Community Scholarships [everylifefoundation.org], created to support students in the rare disease community facing financial barriers to education. We’re honored to begin this program with the Paula Kovarick Segalman Family Scholarship for ALS [everylifefoundation.org], made possible by the Segalman family, who approached EveryLife to help bring their vision to life in honor of Paula.

The Paula Kovarick Segalman Family Scholarship for ALS is a renewable scholarship for up to $5,000 for students who maintain a minimum 2.5 GPA on a 4.0 scale (or equivalent). It is available to individuals who have faced financial hardships due to an ALS diagnosis, either their own or that of an immediate family member. This scholarship is not degree specific, but students must plan to enroll in a full-time undergraduate study at an accredited two- or four-year college, university, or vocational school for the entire upcoming academic year. Learn More and Apply: https://everylifefoundation.org/segalman/ [everylifefoundation.org]

We are hiring a postdoctoral researcher!
An exciting opportunity to join our new project on MRI-based imaging biomarker development in ALS. The appointment will be at the Center for Magnetic Resonance Research (CMRR) at the University of Minnesota. The CMRR is one of the world’s premier magnetic resonance imaging facilities, with considerable expertise in imaging physics, engineering, and clinical research. Further details and a formal application link are available at

https://hr.myu.umn.edu/jobs/ext/359206

CVs and/or informal inquiries about the position may be emailed to Pramod Pisharady at email hidden; JavaScript is required before submitting a formal application.


MDA provides support for research throughout the pipeline of drug development from discovery research through clinical trials. Funding opportunities exist for both academic investigators as well as for biotech and pharma seeking to develop therapies for neuromuscular disease.

Learn about all our grant programs and find deadlines and instructions on how to apply.

Sean M. Healey International Prize for Innovation in ALS

The annual Sean M. Healey International Prize for Innovation in ALS is a global prize celebrating excellence in research for a team of investigators who catalyze exceptional discoveries leading to a transformative advance in therapy development in ALS. Novel advances could include, but are not limited to, technologies, tools or targets that lead to new insight, drug development, or clinical trial improvement.

Nominations Due: Wednesday, July 9th at 5pm EST

Presentation of award: International Symposium on ALS/MND December 5-7, 2025

Award: $50,000 USD and travel reimbursement up to $2,500 USD to attend International Symposium on ALS/MND

To learn more about the 7th annual prize and how to nominate a team, click here.

Please send questions to: email hidden; JavaScript is required

To learn more about all of the awards offered through the Healey & AMG Center:

Prizes Recognizing Innovation in ALS

To learn more about the Healey & AMG Center for ALS: https://www.massgeneral.org/neurology/als/

Gupta Family Endowed Prize for Innovation in ALS Care

The Gupta Family Endowed Prize for Innovation in ALS Care is an annual global prize to honor ground-breaking new approaches that lead to exceptional care for individuals living with amyotrophic lateral sclerosis (ALS).

This annual prize is awarded to a nominated team that has developed promising new approaches to improving care for people living with ALS. Examples of ALS care

innovation include but are not limited to assistive technology, multidisciplinary care,

communication and education, trials, nutrition.

Nominations Due: Friday, May 30th at 5pm EST

Presentation of award: NEALS Annual Meeting October 7-10, 2025

Award: $40,000 USD and travel reimbursement up to $2,500 USD to attend the Annual NEALS Meeting

To learn more about the 5th annual prize and how to nominate a team, click here.

Advancing ALS Discovery through Artificial Intelligence and Natural Language Processing

Overview:

ALS Finding a Cure® is pleased to announce a Request for Proposals (RFP) to support innovative research projects leveraging Artificial Intelligence (AI) and Natural Language Processing (NLP) to advance ALS discovery. This funding opportunity seeks to catalyze transformative research that integrates AI-driven methodologies to improve diagnosis, biomarker identification, disease progression modeling, and therapeutic target discovery in ALS.

Background:

ALS is a devastating neurodegenerative disease with no cure and limited therapeutic options. AI and NLP offer the potential to revolutionize ALS research by enabling the extraction of meaningful insights from complex datasets, including electronic health records (EHRs), published medical literature, clinical trial data, omics datasets, and real-world patient-reported data. Through this RFP, we aim to support high-impact projects that will enhance our understanding of ALS and accelerate novel therapeutic strategies.

Examples of large data sources include but are not limited to:

Answer ALS, ALS Compute, UK Bio Bank. ProACT, NeuroBank, Project MINE, ALS TDI ARC, and other commercially available health record data

Scope of the RFP:

We invite applications proposing AI and/or NLP-based approaches to address critical challenges in ALS research. Areas of interest include, but are not limited to:

· Drug Discovery and Repurposing: Machine learning-based identification of potential ALS drug targets or repurposed therapies using AI-driven drug screening techniques.

· Biomarker Discovery and Validation: Integration of AI/NLP with multi-omics, imaging, and patient-reported outcomes to identify and validate ALS biomarkers.

· AI-Driven Early Diagnosis: Use of AI and NLP for automated extraction of early clinical features from EHRs, speech and language analysis, or fluid biomarker or imaging data to improve early detection of ALS.

· Pathomechanistic Knowledge Graphs: Integration of NLP tools with the published medical literature for discovery of previously underappreciated mechanistic targets.

· Disease Progression Modeling: AI-based analysis of longitudinal clinical and /or biomarker data to enhance prediction models for disease progression and stratification of patients.

· Optimizing Clinical Trials: AI-powered patient stratification, automated NLP-based extraction of clinical endpoints from records, virtual comparison groups and trial recruitment optimization.

· Data Subtypes: Use of AI technology to separate ALS from Controls and to find ALS subtypes in the Answer ALS data set by combining clinical, biomarker, genetic and motor neuron omics data.

Eligibility Criteria:

· Open to researchers at academic, medical, and research institutions worldwide.

· Multidisciplinary and collaborative proposals integrating AI/NLP expertise with ALS clinical or biological research are encouraged.

· Prior AI/NLP experience is not required, but partnerships with computational experts are recommended.

· Pharmaceutical & Clinical Collaboration: Synergistic collaboration between industry and institutions with data-driven models encouraged.

Funding and Award Information:

· Grant Duration: Up to 2 years

· Funding Amount: Up to $400,000 USD total (inclusive of both direct and indirect costs)

· Number of Awards: 3 awarded teams

· Indirect Costs: Maximum of 15%

Application Timeline:

· Initial Letter of Interest (LOI) Submission Due: Friday May 23, 2025

· Notification of LOI Submission: June 2025

· Full Proposals Due: Wednesday August 8, 2025

· Project Start Date: Wednesday October 1, 2025

Review Criteria:

Proposals will be evaluated based on:

1. Scientific Merit and Innovation: Potential of AI/NLP methodologies to transform ALS research.

2. Feasibility and Approach: Strength of study design, methodology, and data integration strategy.

3. Investigative Team: Expertise and collaborative potential of the research team.

4. Translational Potential: Likelihood of findings contributing to improved ALS diagnostics, treatments, or patient outcomes.

How to Apply:

Application Process

This will be a two-step process. Applicants will first submit a formal Letter of Interest. Selected applicants will then be asked to submit a full proposal if chosen.

1. First Step – Letter of Intent:

Letter of Intent should be max 2 pages in length and include the following:

o Proposal Title

o Team’s highlighted experience

o Brief overview of project

o Expected Outcomes

2. Second Step - Expanded Application

·If Letter of Interest is accepted, you will be asked to provide a cover letter

addressed to ALS Finding a Cure and the Leandro P. Rizzuto Foundation

including:

o Proposal Title

o Total costs (15% overhead cap)

o Number of milestones and related costs (to equal amount above)

o List of all investigators and institutions

o Name and contact information for person(s) responsible for contracts

o Address for mailing of payments

·Provide a study plan including:

o A brief abstract suitable for media release to the lay public if the application is successful

o Project Plan, Background, and Timeline (max. 5 pages) including:

· Study background and rationale/significance

· Study objectives/specific aims

· Supporting/preliminary data;

· Experimental design/research plan;

· Source of data and confirmation of access;

· Detailed itemized budget and budget justification

· Description of study milestones, including the costs associated and timeline of specific deliverables

· Any research funding from other funding sources that relates to the proposed work

·Signed and dated investigator CVs

·Financial Disclosure Form: use either NIH Form

https://ethics.od.nih.gov/forms450), or institutional form.

Submit LOI to: https://app.box.com/f/33b7d67838bb4bc987eb5e65686411ea

For more information on submission guidelines please see:

https://www.alsfindingacure.org/2025-als-finding-a-cure-request-for-proposals/

Please submit questions to email hidden; JavaScript is required

ALS Finding a Cure® is committed to supporting cutting-edge research that will drive meaningful advancements in ALS discovery through AI and NLP.

The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital is seeking applications of experimental therapies for inclusion in our newest initiative, ALS MyMatch. This is a patient-centered, efficient approach for screening investigational products in early-phase biomarker driven (Phase 1b/2a) clinical trials in ALS across several experienced trial-ready enrolling centers.

In addition to evaluating safety and tolerability each ALS MyMatch trial design will be customized to answer specific scientific questions of interest relevant to the applicant’s investigational product. The best fit for primary scientific scope of a MyMatch clinical trial includes biological efficacy, target engagement, CNS penetrance, pharmacokinetics and/or dose finding trials.

This program is not for Phase 1 healthy volunteer studies.

Please consider applying to the HEALEY ALS Platform trial if the primary objective is a clinical efficacy trial in ALS.

For more information about the ALS MyMatch Trial visit:

https://www.massgeneral.org/neurology/als/news/healey-center-launches-als-my-match-program

We encourage applications for investigational products from the academic and industry community to be considered for inclusion in ALS MyMatch in 2025.

The first 2-3 selected applicants will receive partial funding support from the Healey & AMG Center.

Timeline for Submission:

Release Date: Friday April 4, 2025

Informational Webinar: Thursday, April 10, 2025 05:00 PM EDT

Application Due Date: Friday, May 16, 2025

Review Criteria:

1. Relevance of target to human disease

2. Pre-clinical data to support target and therapy

3. Clinical trial readiness (availability of compound and placebo (if applicable), and regulatory approval status)

4. Availability of relevant biomarkers for participant selection as well as target engagement